Brazil Dermatology Drugs Market Analysis Report 2022 to 2030

Brazil Dermatology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Brazil dermatology drugs market will reach a value of $1037.35 Mn from $425 Mn in 2022, growing at a CAGR of 11.8% during 2022-2030. The market is primarily dominated by local players such as Neo Química, Eurofarma, and EMS S.A. The market is driven by Telemedicine, OTC, and government regulations. The dermatology drug market in Brazil is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel.

ID: IN10BRPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: Brazil AUTHOR: Dr. Vishwa Modhia

Buy Now

Brazil Dermatology Drugs Market Analysis Summary

By 2030, it is anticipated that the Brazil dermatology drugs market will reach a value of $1037.35 Mn from $425 Mn in 2022, growing at a CAGR of 11.8% during 2022-30.

With a 9.1% GDP expenditure on healthcare, Brazil has the largest healthcare market in all of Latin America. Local pharmaceutical firms in Brazil play a significant role in the dermatology drug market by providing more affordable alternatives to branded medications and supporting the overall growth of the nation's healthcare industry.

With sales of $15.02 Bn in 2020, Brazil is one of the top seven pharmaceutical and drug markets in terms of size. Dermatology is considered a specialty field in Brazil and is generally only covered by private insurance plans, which make up a portion of total healthcare spending.

brazil dermatology drugs market analysis

Market Dynamics

Market Growth Drivers Analysis

Telemedicine, including tele-dermatology, has become more widely used in Brazil as a result of the expanding use of technology in healthcare. With the help of this trend, more people can now consult dermatologists in the convenience of their own homes, expanding access to dermatology services.

Many Brazilian consumers are turning to self-diagnosis and self-treatment, including the use of over-the-counter (OTC) dermatology drugs, as a result of the expansion of online information and resource availability. Growing the number of Public-Private Partnerships (PPPs) in Brazil will draw strategic investors and increase funding and system efficiency. These factors favor the growth of Brazil's dermatology drugs market.

Market Restraints

Brazil's healthcare market is price-driven, with domestically produced goods clearly having a price advantage. As a result, drug imports from countries other than Brazil will be deterred. Another significant obstacle is the high concentration of the Brazilian distribution network, which is controlled by a small number of national and regional organizations. Local distributors handle 65% to 75% of pharmaceutical distribution, with only 25% to 35% going directly to retail.

Competitive Landscape

Key Players

EMS S.A. (BRA)
Eurofarma (BRA)
Neo Química (BRA)
Aché (BRA)
Cristália (BRA)
GlaxoSmithKline
Pfizer
Sanofi
Johnson & Johnson

Recent Notable Updates

August 2022: Exzell Pharma, a Canadian healthcare company, has been acquired by the Brazilian pharmaceutical company Biolab. The acquisition improves the Brazilian company's global operations. Exzell keeps a portfolio with a heavy emphasis on dermatology, vitamins, and dietary supplements.

Healthcare Regulations and Reimbursement Policies

The Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária or ANVISA) is in charge of regulating the approval and marketing of dermatology medications in Brazil. The federal organization ANVISA is in charge of ensuring the caliber, security, and effectiveness of health products in Brazil, including medications for treating skin conditions.

At least 70% of the Brazilian population receives their primary healthcare from the country's Unified Healthcare System (SUS). The public health system also provides free medication for some chronic diseases in addition to medical diagnostics and treatment.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Dermatology Drugs Market Segmentation

The Dermatology Drugs Market is segmented as mentioned below

By Disease (Revenue, USD Billion):

Psoriasis
Acne Vulgaris
Atopic Dermatitis
Eczema
Rosacea
Itchthyosis
Vitiligo
Others

By Route Of Administration (Revenue, USD Billion):

Oral
Parenteral
Topical

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.